Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

New England Journal of Medicine(2021)10.1056/nejmoa2101016Source: DataRank Database

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women is a research paper published in New England Journal of Medicine (2021). On theSindex it has a DataRank of 8.3. It has been cited 869 times, with 100 citing works in its 1-hop citation network.

N/A

8.3DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access869 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02720094

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)OA: bronzeTopics (115)IDs (PubMed, PMC)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 12%Citation Network 88%

Base Score Contribution

1.0

From this paper's citation signal

Citation Network Contribution

7.3

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

The Potential of Long-Acting, Injectable PrEP, and Impediments to its Uptake
Journal of Urban Health202317 citations8 referencesContributes 0.361
Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
Journal of the International AIDS Society202229 citations11 referencesContributes 0.309
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023
HIV Medicine2023172 citations18 referencesContributes 0.286
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
New England Journal of Medicine2024444 citations28 referencesContributes 0.218
Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study
The Lancet202547 citations18 referencesContributes 0.215

Authors (65)

Deborah Donnell ORCID,Meredith E. Clement ORCID,Brett Hanscom ORCID,Leslie Cottle,Lara E. Coelho ORCID

Live enrichment

PubMed:34379922 PMC:PMC8448593

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068613

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068617

National Institute of Allergy and Infectious Diseases

Grant: UM1AI068619

NIAID NIH HHS

Grant: P30 AI050410

NIAID NIH HHS

Grant: UM1 AI069534

NIAID NIH HHS

Grant: UM1 AI069496

NIAID NIH HHS

Grant: UM1 AI154468

NIAID NIH HHS

Grant: UM1 AI069424

NIAID NIH HHS

Grant: P30 AI045008

NIMH NIH HHS

Grant: R25 MH067127

NIAID NIH HHS

Grant: UM1 AI069399

NIAID NIH HHS

Grant: K23 AI137121

NIAID NIH HHS

Grant: UM1 AI069519

National Institutes of Health

Grant: 5UM1AI068619-09

LOC: HIV Prevention Trials Network

National Institutes of Health

Grant: 3UM1AI068617-20S1

HPTN SDMC: HPTN 096 Getting to Zero among Highest HIV Incidence (HHI) Men who have Sex with Men (MSM) in the American South: Testing an Integrated Strategy

National Institutes of Health

Grant: 5UM1AI068613-16

LC: HIV PREVENTION TRIALS NETWORK

Fundação para a Ciência e a Tecnologia, I.P.

Grant: PTDC/CCI-BIO/29266/2017

Deep Drug Discovery and Deployment

Gilead Sciences

ViiV Healthcare

bronzeLicense: http://www.nejmgroup.org/legal/terms-of-use.htm

publisherhttp://www.nejm.org/doi/pdf/10.1056/NEJMoa2101016

https://doi.org/10.1056/nejmoa2101016

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448593

https://pubmed.ncbi.nlm.nih.gov/34379922

https://dx.doi.org/10.1056/nejmoa2101016

Fields of Study

0302 clinical medicine03 medical and health sciences

MeSH Terms

HumansHIV InfectionsPyridonesDelayed-Action PreparationsHIV Integrase InhibitorsAnti-HIV AgentsAdministration, OralInjections, IntramuscularDrug Administration ScheduleDouble-Blind MethodHomosexuality, MaleDrug ResistanceAdultAgedMiddle AgedFemaleMaleDiketopiperazinesMedication AdherenceYoung AdultIntention to Treat AnalysisPre-Exposure ProphylaxisTenofovirTransgender Persons

Keywords

Prevention (rcdc)MaleDrug ResistanceHealth Disparities (rcdc)Administration, OralHIV InfectionsDrug Resistance (mesh)11 Medical and Health Sciences (for)Medical and Health SciencesClinical Research (rcdc)Medication Adherence (mesh)Medical SpecialtiesMedicine and Health SciencesHPTN 083 Study TeamMinority Health32 Biomedical and Clinical Sciences (for-2020)Male (mesh)Intramuscular (mesh)42 Health Sciences (for-2020)IntramuscularHumans (mesh)Young Adult (mesh)3 Good Health and Well Being (sdg)Sexual and Gender Minorities (SGM/LGBT*) (rcdc)HomosexualityIntention to Treat Analysis (mesh)Middle AgedIntention to Treat AnalysisHealth DisparitiesInfection (hrcs-hc)Infectious DiseasesAdministrationHIV/AIDSMinority Health (rcdc)FemalePublic HealthInfectionOralAdultGeneral & Internal Medicine (science-metrix)Anti-HIV AgentsPyridonesTenofovir (mesh)Clinical SciencesClinical Trials and Supportive ActivitiesClinical Trials and Supportive Activities (rcdc)610Sexual and Gender Minorities (SGM/LGBT*)HIV Infections (mesh)Transgender PersonsInjections, IntramuscularDrug Administration ScheduleInjectionsMedication AdherenceYoung AdultDouble-Blind MethodClinical ResearchGeneral & Internal MedicineHealth Sciences4206 Public Health (for-2020)Middle Aged (mesh)Internal MedicineHumansHIV Integrase InhibitorsHomosexuality, MaleTenofovirDouble-Blind Method (mesh)3202 Clinical Sciences (for-2020)Oral (mesh)AgedPre-Exposure Prophylaxis (mesh)HIV/AIDS (rcdc)Biomedical and Clinical SciencesAged (mesh)HIV Integrase Inhibitors (mesh)PreventionDrug Administration Schedule (mesh)Anti-HIV Agents (mesh)Good Health and Well BeingPyridones (mesh)Transgender Persons (mesh)Infectious Diseases (rcdc)Female (mesh)Delayed-Action PreparationsAdult (mesh)Delayed-Action Preparations (mesh)Sexually Transmitted InfectionsPre-Exposure ProphylaxisSexually Transmitted Infections (rcdc)

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justice